BioLineRx Ltd. (TASE: BLRX)
Health Care · Biotechnology · IL
₪0.01
-7.69% today · -42.9% 1Y
BioLineRx Ltd. (TASE: BLRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.56M and employs 22 people.
Over the last twelve months the share price has lost 42.9%, trading between 0.01 and 0.02.
Tweenvest scores BioLineRx Ltd. across four factors: quality 38/100, value 37/100. Its strongest factor is quality.
BLRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.56M
- Revenue (TTM)
- $1.39M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- ₪0.02
- 52-week low
- ₪0.01
- Avg volume (3M)
- —
- Shares outstanding
- 2.99B
- Employees
- 22
- Next earnings
- —
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- ISIN
- IL0011015182
- Founded
- 2003
- Listed since
- Feb 6, 2007
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharmala Biotech Holdings Inc.CNSX: MDMA | $12.02M | CA$0.16 | -27.91% |
| EOM Pharmaceuticals Holdings, Inc.OTCPK: IMUC | $12.02M | $0.10 | -40.21% |
| Karyopharm Therapeutics Inc.NasdaqGS: KPTI | $11.74M | $0.52 | -5.27% |
| AEON Biopharma, Inc.NYSEAM: AEON | $11.57M | $0.23 | -15.94% |
| Eagle Pharmaceuticals, Inc.OTCPK: EGRX | $11.53M | $0.89 | -8.76% |
| Aelis Farma SAENXTPA: AELIS | $11.50M | €0.75 | -5.88% |
| Pluri Inc.NasdaqCM: PLUR | $11.48M | $0.93 | -2.44% |
| Celyad Oncology SAENXTBR: CYAD | $11.43M | €0.23 | +13.50% |
Figures last refreshed Oct 18, 2026.